ValiRx PLC
10 August 2026
10 August 2026
ValiRx PLC
("ValiRx" or the "Company")
Cytolytix Patent Update
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, is pleased to provide the following updates on its majority owned subsidiary Cytolytix Limited ("Cytolytix").
Cytolytix's European Patent application "Polyleucine-Based Peptides As Anti-Cancer Agents" (application No. 20793085.0) has received formal notification of the European Patent Office's intention to grant a European patent. This patent, licensed from King's College London, forms a key part of the Cytolytix intellectual property portfolio.
Once granted, this second European patent will strengthen Cytolytix's intellectual property position and the Directors believe affirms the investment in the innovative platform ValiRx has developed over the last few years.
This notice, alongside the European grant of the original peptide formulation patent "Nanoparticle for Anti-Cancer Peptides and Uses Thereof", announced on 27 May 2026, further strengthens the Company's ability to attract external investment as well as increasing the Company's offerings for licensing and ongoing partnership discussions. A further announcement will be made in due course on receipt of the patent grant.
Whilst these two patent families represent core IP for Cytolytix, ValiRx filed for additional patent protection on 26 May 2026 covering new inventions relating to its second-generation delivery platform based on novel lipid formulations of the oncolytic peptide.
The new patent application includes data demonstrating induction of immunogenic cell death in Triple Negative Breast Cancer Cells, a key component of the mechanism of action that could provide enhanced and more durable responses when translated to the clinical setting.
Mark Eccleston, CEO of ValiRx, commented "The notification of intention to grant a second core patent is a significant milestone for Cytolytix, confirming the novelty of the platform and providing a solid base to build on with further IP developed in house. Having a range of proprietary formulations allows us to explore differentiated products for various routes of administration and across multiple clinical applications in the human and veterinary markets. This has been possible through the expertise developed in Inaphaea as well as through our NAMs capability partners at ScreenIn3D, Voxcell and Bioreparia.
"The demonstration of release of immune-activating signals is a very encouraging step towards demonstrating the anticipated immune boost feature of this class of therapeutics which is being explored using advanced NAMs approaches in house and through our partners. It is also a key driver for our comparative oncology approach in pet patients with spontaneous tumours and in real patients with intact immune systems."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.
Cautionary statement
Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching videosummaries and seeing what other shareholders have to say. Navigate to our Interactive Investorhub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
|
|
ValiRx plc Dr Mark Eccleston, CEO |
Tel: +44 115 784 0026 Mark.Eccleston@valirx.com |
|
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker) Damon Heath
|
Tel: +44 (0) 20 4530 6926 |
|
V Formation (Public Relations)
Jocelyn Braithwaite
|
Tel: +44 (0) 115 646 5491 |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.